ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005231

hepatitis C virus infection

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. hepatitis C virus infection. Diseases, record MONDO_0005231. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005231

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
hepatitis C virus infection
Open Targets
Open Targets ID
MONDO_0005231
Open Targets
Other names
HCV infection, Hepatitis C (disorder), Hepatitis C virus caused hepatitis, Hepatitis C virus hepatitis, Hepatitis non-A non-B (disorder), NANBH, Viral hepatitis C, Viral hepatitis C (disorder), acute hepatitis C with hepatic coma, hepatitis C, hepatitis C infection, hepatitis nonA nonB, hepatitis type C, non-A, non-B Hepatitis
Open Targets
Disease Ontology
DOID:1883
Disease Ontology
MeSH
D006526
MeSH
NCI Thesaurus
C3098
NCI Thesaurus
Highest stage of its drugs
Approval, for 17 of its 206 drugs, from ClinicalTrials.gov, DailyMed and TTD
Open Targets

Drugs206

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
RIBAVIRINCHEMBL1643Small moleculeApprovalClinicalTrials.gov and TTD497495495Drugs and targets
SOFOSBUVIRCHEMBL1259059Small moleculeApprovalClinicalTrials.gov, DailyMed and TTD278272271Drugs and targets
PEGINTERFERON ALFA-2BCHEMBL1201561ProteinApprovalTTD999675Drugs and targets
LEDIPASVIRCHEMBL2374220Small moleculeApprovalDailyMed949191Drugs and targets
DACLATASVIRCHEMBL2023898Small moleculeApprovalTTD888787Drugs and targets
VELPATASVIRCHEMBL3545062Small moleculeApprovalTTD878685Drugs and targets
RITONAVIRCHEMBL163Small moleculeApprovalDailyMed and TTD666464Drugs and targets
TELAPREVIRCHEMBL231813Small moleculeApprovalTTD515050Drugs and targets
PARITAPREVIRCHEMBL3391662Small moleculeApprovalDailyMed and TTD524949Drugs and targets
OMBITASVIRCHEMBL3127326Small moleculeApprovalDailyMed and TTD494646Drugs and targets

1 to 10 of 206

See all 206 drugs

Targets156

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
IFNAR1Interferon alpha/beta receptor8Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulatorApprovalhttps://conductscience.org/library/genes/3454Drugs and targets
IFNAR2Interferon alpha/beta receptor8Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulatorApprovalhttps://conductscience.org/library/genes/3455Drugs and targets
IMPDH1Inosine-5'-monophosphate dehydrogenase (IMPDH)4Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor; Inosine-5'-monophosphate dehydrogenase 1 inhibitorApprovalhttps://conductscience.org/library/genes/3614Drugs and targets
HMGCR3-hydroxy-3-methylglutaryl-coenzyme A reductase3HMG-CoA reductase inhibitorPhase 2https://conductscience.org/library/genes/3156Drugs and targets
MPLThrombopoietin receptor3Thrombopoietin receptor agonistPhase 3https://conductscience.org/library/genes/4352Drugs and targets
PDCD1Programmed cell death protein 13Programmed cell death protein 1 inhibitorPhase 2https://conductscience.org/library/genes/5133Drugs and targets
PPIAPeptidyl-prolyl cis-trans isomerase A3Cyclophilin A inhibitor; Cyclophilin A modulatorPhase 3https://conductscience.org/library/genes/5478Drugs and targets
TLR7Toll-like receptor 73Toll-like receptor 7 activator; Toll-like receptor 7 agonist; Toll-like receptor 7 antagonistPhase 1/2https://conductscience.org/library/genes/51284Drugs and targets
TLR9Toll-like receptor 93Toll-like receptor 9 agonist; Toll-like receptor 9 antagonistPhase 1/2https://conductscience.org/library/genes/54106Drugs and targets
CASP1Caspase2Caspase inhibitor; Caspase-1 inhibitorPhase 2https://conductscience.org/library/genes/834Drugs and targets

1 to 10 of 156

See all 156 targets

Trials933

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 18 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01070550PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)4,6802016-06-15Hepatitis C, ChronicPEGINTERFERON ALFA-2A, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT00081770Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)Phase 34,4692009-10-30Hepatitis C, ChronicPEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT01667081Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)2,4382022-06-06Hepatitis CGRAZOPREVIRIts record names the diseaseClinicalTrials.gov
NCT00724893Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)2,4302013-11-20Hepatitis C, Chronic, Hepatitis CPEGINTERFERON ALFA-2B, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT01066793PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b2,3432016-05-09Hepatitis C, ChronicPEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2BIts record names the diseaseClinicalTrials.gov
NCT00039871PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)Phase 32,3332008-12-11Hepatitis, Hepatitis C, Chronic, Fibrosis, Liver CirrhosisPEGINTERFERON ALFA-2B, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT00727311Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)2,3022011-01-10Hepatitis C, Chronic, Hepatitis CPEGINTERFERON ALFA-2B, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT00727259Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)1,9952009-08-06Hepatitis C, ChronicPEGINTERFERON ALFA-2B, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT01066819PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b1,6562016-08-08Hepatitis C, ChronicPEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRINIts record names the diseaseClinicalTrials.gov
NCT02219490
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Phase 31,5962023-04-07Chronic Hepatitis C Virus (HCV) Infection Genotype 1DASABUVIR, OMBITASVIR, PARITAPREVIR, RIBAVIRIN, RITONAVIRIts record names the diseaseClinicalTrials.gov

1 to 10 of 933

See all 933 trials

Comparisons in its trials228

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
GZR 100 mg + EBR 50 mg +/- RBV vs Other GZR Regimen: Number of Participants Who Experienced a Drug-Related Serious Adverse Event (SAE) During the Long-Term Follow-Up1 of 1,9091 of 5262,435NCT01667081Trial comparisons
GZR 100 mg + EBR 50 mg +/- RBV vs Other GZR Regimen: Number of Participants Who Experienced an Event of Clinical Interest (ECI) During the Long-Term Follow-Up98 of 1,9094 of 5262,435NCT01667081Trial comparisons
GZR 100 mg + EBR 50 mg +/- RBV vs Other GZR Regimen: Number of Participants Who Experienced a Drug-Related Adverse Event (AE) During the Long-Term Follow-Up1 of 1,9091 of 5262,435NCT01667081Trial comparisons
Stage 1 Participants vs Stage 2 Participants: Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2)76 of 1,302142 of 1,1282,430NCT00724893Trial comparisons
Mono-infected With HCV vs Co-infected With HCV and HIV: Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment551 of 1,01032 of 721,082NCT00724854Trial comparisons
Mono-infected With HCV vs Co-infected With HCV and HIV: Number of Participants Who Achieved Sustained Virologic Response (SVR)375 of 1,01024 of 721,082NCT00724854Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Serious Adverse Events175 of 517155 of 5331,050NCT00006164Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Development of Hepatocellular Carcinoma (HCC)13 of 51716 of 5331,050NCT00006164Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Variceal Hemorrhage5 of 51711 of 5331,050NCT00006164Trial comparisons
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Ascites32 of 51727 of 5331,050NCT00006164Trial comparisons

1 to 10 of 228

See all 228 comparisons in its trials

Papers from its trials618

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
36790337RESULT1PubMed
32156618RESULT1PubMed
32087176RESULT1PubMed
31570394RESULT1PubMed
31313296RESULT1PubMed
31108015RESULT2PubMed
31078622RESULT1PubMed
30980576RESULT1PubMed
30939489RESULT1PubMed
30861150RESULT1PubMed

1 to 10 of 618

See all 618 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005231

GET https://conductscience.org/api/diseases/v1/MONDO_0005231/drugs?page=2

API referenceFor AI assistants